- Home
- ESCA vs ZNTL Comparison
ESCA vs ZNTL Comparison
Compare ESCA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESCA | ZNTL |
|---|---|---|
| Founded | 1922 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 162.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESCA | ZNTL |
|---|---|---|
| Price | $14.61 | $2.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 17.6K | ★ 1.6M |
| Earning Date | 02-25-2026 | 03-25-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $241,540,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $15.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.41 | $1.01 |
| 52 Week High | $16.99 | $3.95 |
Technical Indicators
Market Signals| Indicator | ESCA | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 47.69 |
| Support Level | $14.50 | $2.21 |
| Resistance Level | $14.96 | $2.85 |
| Average True Range (ATR) | 0.37 | 0.29 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 87.39 | 13.89 |
Price Performance
Historical ComparisonAbout ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.